S5E5: Mock Case Interview: Unstructured Case
Strategy Simplified
00:00
What's the Key Difference Between the Regulatory Pathways?
The f d a's going toa mandate. They're gong to say, ok, fr o to be able to sell this to customers. And it's this back and forth conversation with the fda. The p m a is more costly because of clinical trialsthat's going to take us longer to develop the product. Yet, yet, we're talking about health care. We're talking about increasing, you know, patients treated, improving patients lives. So i think that we're probably going to come up with devices that fit into either of these regulatory pathways.
Transcript
Play full episode
